NewAmsterdam Pharma Company NV Ordinary Shares

NewAmsterdam Pharma Company NV Ordinary Shares

Yahoo Finance • 12 days ago

How Novartis' Double-Stacked Failures Reverberated Through Biopharma

Novartis and Ionis' high-profile Lp(a) flop on Friday reverberated through biotech stocks on Tuesday, leading to a widespread drop. Continue Reading... Full story

Yahoo Finance • 12 days ago

Novartis Trial Failure Sparks Biopharma Options Frenzy

Biopharma stocks are dominating the unusual options volume list today, after a high-profile clinical trial failure from Novartis AG (NYSE:NVS) sent shockwaves through the sector. NVS is headed for its worst single-session performance on re... Full story

Yahoo Finance • 12 days ago

How Novartis And Ionis' High-Profile Failure Reverberated Through Biopharma

Novartis and Ionis' high-profile Lp(a) flop on Friday reverberated through biotech stocks on Tuesday, leading to a widespread drop. Continue Reading... Full story

Yahoo Finance • 12 days ago

Novartis drops 13% on trial failure, dragging Dyne and Sarepta

[Scientist use ai technology, biotechnology for Medical research and development of scientific lab. Medical Research Laboratory for Test and analysis chromosome DNA genetic.] Swiss drugmaker Novartis' (NVS [https://seekingalpha.com/symbol... Full story

Yahoo Finance • 2 months ago

Attovia Therapeutics Appoints John W. Smither to Board of Directors

SAN CARLOS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high u... Full story

Yahoo Finance • 2 months ago

Cambrex, Snapdragon Chemistry, and Q1 Scientific Recognized for Innovation and Sustainability in Pharma

EAST RUTHERFORD, N.J., July 7, 2026 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), proudly announces that Snapdragon Chemistry, a Cambrex company, together with NewAmsterdam Pharma, ha... Full story

Yahoo Finance • 3 months ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NewAmsterdam Pharma N.V. NAARDEN, The Netherlands and MIAMI, July 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing... Full story

Yahoo Finance • 3 months ago

NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026

NAARDEN, the Netherlands and MIAMI, July 01, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medici... Full story

Yahoo Finance • 3 months ago

Billionaire Stanley Druckenmiller Likes This Small-Cap Pharma Stock in 2026

We just covered the 10 Best Non-AI Stocks to Buy According to Billionaire Stanley Druckenmiller. NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) ranks #5 (see 5 Best Non-AI Stocks to Buy According to Billionaire Stanley Druckenmiller). Dr... Full story

Yahoo Finance • 4 months ago

Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge

FCPM III Services B.V. disclosed a new position in Damora Therapeutics(NASDAQ:DMRA) as of March 31, 2026, acquiring 2,441,000 shares for an estimated $65.63 million based on quarterly average pricing. What happened According to a Securit... Full story

Yahoo Finance • 4 months ago

Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean

On May 15, 2026, FCPM III Services B.V. reported a sale of 818,460 shares of Dyne Therapeutics(NASDAQ:DYN), an estimated $14.11 million trade based on quarterly average pricing. What happened According to a Securities and Exchange Commis... Full story

Yahoo Finance • 6 months ago

This Biotech Was Quietly Bought Before a $58 Per Share Takeout

On February 17, 2026, FCPM III Services B.V. disclosed a buy of 1,489,096 RAPT Therapeutics(NASDAQ:RAPT) shares, an estimated $46.24 million trade based on quarterly average pricing. What happened According to a Securities and Exchange C... Full story

Yahoo Finance • 9 months ago

National Presto, Garrett Motion, and More Stocks See Action From Activist Investors

Activists also report to the SEC on Universal Technical Institute, Impinj, Garrett Motion, and NewAmsterdam Pharma. Continue Reading... Full story

Yahoo Finance • 10 months ago

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December

NAARDEN, The Netherlands and MIAMI, Nov. 25, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medici... Full story

Yahoo Finance • 10 months ago

Biotech Stock Gets Booted in Latest Fund Update

Key Points Sold 1,447,267 shares, a net position change of $110.43 million Post-trade stake: 0 shares, $0 value The position was previously 13.8% of the fund's AUM as of the prior quarter, marking a significant portfolio shift These 10 st... Full story

Yahoo Finance • 10 months ago

Stanley Druckenmiller's Strategic Moves: Exiting Philip Morris International Inc with a -3. ...

This article first appeared on GuruFocus. Insights into Stanley Druckenmiller (Trades, Portfolio)'s Third Quarter 2025 Portfolio Adjustments Warning! GuruFocus has detected 6 Warning Signs with NTRA. Is NTRA fairly valued? Test your thes... Full story

Yahoo Finance • 11 months ago

8Dell, 89bio, MBX Biosciences and More Stocks See Action From Activist Investors

13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities. Continue Reading View Comments... Full story

Yahoo Finance • last year

NewAmsterdam Pharma reports Q2 results

* NewAmsterdam Pharma press release [https://seekingalpha.com/pr/20190665-newamsterdam-pharma-provides-corporate-update-and-reports-second-quarter-financial-results] (NASDAQ:NAMS [https://seekingalpha.com/symbol/NAMS]): Q2 net loss of $1... Full story

Yahoo Finance • last year

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

–European marketing authorization application on track in 2H25 – – PREVAIL Phase 3 CVOT remains on track – – Late Breaking BROADWAY and TANDEM data presented at EAS 2025 and simultaneously published in The New England Journal of Medicine... Full story

Yahoo Finance • last year

Obicetrapib shows promise in reducing Alzheimer's biomarkers

NAARDEN/MIAMI - NewAmsterdam Pharma (NASDAQ:NAMS) announced Wednesday that its experimental drug obicetrapib significantly reduced plasma p-tau217, a key biomarker of Alzheimer’s disease pathology, according to data from a prespecified ana... Full story